Table 1.
Demographic and clinicopathologic characteristics of the 332 AML patients undergoing allogeneic HSCT.
| Demographic or Characteristic | No. of patients | % |
|---|---|---|
| Gender | ||
| Male | 202 | 60.8 |
| Female | 130 | 39.2 |
| Age | ||
| <50 | 300 | 90.4 |
| ≥50 | 32 | 9.6 |
| WBC (*10E9/L) | ||
| <10 | 95 | 28.6 |
| 10–30 | 82 | 24.7 |
| ≥30 | 145 | 43.7 |
| Missing | 10 | 3.0 |
| Cytogenetics risk classification | ||
| Favorable | 77 | 23.2 |
| Intermediate | 198 | 59.6 |
| Adverse | 57 | 17.2 |
| Pre-MRD | ||
| MRDpos | 98 | 29.5 |
| MRDneg | 222 | 66.9 |
| missing | 12 * | 3.6 |
| Stage at HSCT | ||
| CR1 | 274 | 82.5 |
| >CR1 | 58 | 17.5 |
| KPS | ||
| ≥90 | 293 | 88.3 |
| <90 | 39 | 11.7 |
| Time from diagnosis to transplant in months | ||
| <6 months | 282 | 84.9 |
| 6–12 months | 40 | 12.1 |
| >12 months | 10 | 3.0 |
| Conditioning intensity | ||
| BuCy/TBICy | 332 | 100.0 |
| Donor type | ||
| Sibling donors | 125 | 37.7 |
| Unrelated donors | 73 | 22.0 |
| Haplo-identical donors | 132 | 39.7 |
| Cord blood | 2 | 0.6 |
| HLA | ||
| Matched HLA | 181 | 54.5 |
| Mismatched HLA | 151 | 45.5 |
WBC, white blood count; ELN, European LeukemiaNet; MRD, minimal residual disease; HSCT, hematopoietic stem cell transplantation; CR1, first complete remission; CR2, second complete remission; KPS, Karnofsky Performance Scale; BuCy, busulfan/cyclophosphamide; TBICy, total body irradiation/cyclophosphamide; HLA, human leukocyte antigen.
*These patients did not enter the establishment of the final prognostic model.